For the year ending 2025-12-31, DWTX had -$8,333,845 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -34,257,370 |
| Loss on foreign exchange | -27,916 |
| Loss on fixed asset disposal | -2,731 |
| Amortization of loan costs | 52,373 |
| Depreciation | 2,063 |
| Reduction in carrying amount of right-of-use asset | 66,115 |
| Loss on debt conversion with related party | -6,134,120 |
| Acquisition of license for research and development | 11,909,667 |
| Deferred tax expense (benefit) | 221,096 |
| Share-based compensation expense | 355,642 |
| Increase in prepaid expenses and other current assets | 208,687 |
| (decrease) increase in accounts payable | -532,607 |
| Increase (decrease) in accrued expenses and other liabilities | 608,290 |
| Net cash used in operating activities | -15,618,651 |
| Proceeds from public offering of common stock, net of offering costs | 4,252,245 |
| Proceeds from loan with related party, net of fees | 3,000,000 |
| Proceeds from issuance of shares on atm, net of cash fees paid | 86,366 |
| Cash payment of issuance costs | 53,805 |
| Net cash provided by financing activities | 7,284,806 |
| Net (decrease) increase in cash | -8,333,845 |
| Cash and cash equivalents, beginning of period | 14,847,949 |
| Effect of foreign currency translation on cash and cash equivalents | 10,640 |
| Cash and cash equivalents, end of period | 6,524,744 |
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)